Dr. Rodica Pop-Busui, MD
Claim this profileUniversity of Michigan
Studies Diabetes Mellitus
Studies Type 1 Diabetes
8 reported clinical trials
11 drugs studied
Affiliated Hospitals
Clinical Trials Rodica Pop-Busui, MD is currently running
Sotagliflozin
for Diabetic Kidney Disease
Powerful new drugs that can prevent or delay end stage kidney disease (ESKD) - so called sodium-glucose cotransporter-2 inhibitors (SGLT2i) - are now available for patients with type 2 diabetes. Whether these drugs have similar effects in patients with type 1 diabetes (T1D) remains unknown because of the few studies in this population, due to concerns about the increase in risk of diabetic ketoacidosis (DKA, a serious, potentially fatal acute complication of diabetes due to the accumulation of substances called ketone bodies) observed with SGLT2i therapy in T1D. One of the few T1D studies conducted to date showed that implementing an enhanced DKA prevention plan can reduce the risk of DKA associated with the SGLT2i sotagliflozin (SOTA) to very low levels. In the present study, a similar DKA prevention program will be used to carry-out a 3-year trial to test the kidney benefit of SOTA in 150 persons with T1D and moderate to advanced DKD. After a 2-month period, during which diabetes care will be standardized and education on monitoring and minimizing DKA implemented, eligible study subjects will be randomly assigned (50/50) to take one tablet of SOTA (200 mg) or a similarly looking inactive tablet (placebo) every day for 3 years followed by 2-months without treatment. Neither the participants nor the study staff will know whether a person was assigned to taking SOTA or the inactive tablet. Kidney function at the end of the study will be compared between the two treatment groups to see whether SOTA prevented kidney function loss in those treated with this drug as compared to those who took the inactive tablet. The DKA prevention program will include participant education, close follow-up with study staff, continuous glucose monitoring, and systematic ketone body self-monitoring with a meter provided by the study. If successful, this study will provide efficacy and safety data that could be used to seek FDA approval of SOTA for the prevention of kidney function decline in patients with T1D and DKD.
Recruiting1 award Phase 3
Biomarkers
for Diabetic Foot Ulcers
This study is a platform study designed to efficiently test multiple biomarkers to identify diabetic foot ulcers (DFUs) with a higher potential for healing versus not healing that ultimately could be applied at the point of care to drive personalized management decisions, and to better inform clinical trials of wound healing interventions
Recruiting1 award N/A5 criteria
More about Rodica Pop-Busui, MD
Clinical Trial Related1 year of experience running clinical trials · Led 8 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Rodica Pop-Busui, MD has experience with
- Fish Oil Concentrate
- Salsalate Oral Tablet
- 670G And 770G Insulin Pump
- Subject's Current Diabetes Therapy
- Observational
- C-myc Biomarker Study
Breakdown of trials Rodica Pop-Busui, MD has run
Diabetes Mellitus
Type 1 Diabetes
Diabetic Foot
Diabetes
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Rodica Pop-Busui, MD specialize in?
Rodica Pop-Busui, MD focuses on Diabetes Mellitus and Type 1 Diabetes. In particular, much of their work with Diabetes Mellitus has involved treating patients, or patients who are undergoing treatment.
Is Rodica Pop-Busui, MD currently recruiting for clinical trials?
Yes, Rodica Pop-Busui, MD is currently recruiting for 3 clinical trials in Ann Arbor Michigan. If you're interested in participating, you should apply.
Are there any treatments that Rodica Pop-Busui, MD has studied deeply?
Yes, Rodica Pop-Busui, MD has studied treatments such as Fish Oil Concentrate, Salsalate Oral Tablet, 670G and 770G Insulin Pump.
What is the best way to schedule an appointment with Rodica Pop-Busui, MD?
Apply for one of the trials that Rodica Pop-Busui, MD is conducting.
What is the office address of Rodica Pop-Busui, MD?
The office of Rodica Pop-Busui, MD is located at: University of Michigan, Ann Arbor, Michigan 48109 United States. This is the address for their practice at the University of Michigan.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.